By integrating TyG-BMI into routine diabetes care (e.g., during annual screenings), clinicians could prioritize intensive monitoring (e.g., hepatic ultrasound for NAFLD, DEXA scans for osteoporosis) or targeted interventions (e.g., SGLT2 inhibitors for cardiorenal protection) for high-risk subgroups, optimizing resource allocation in resource-constrained settings. The gene discussed is SLC5A2; the disease is diabetes mellitus.